Abstract
The possibility that Frost'S ADFR osteoporosis therapy (activate, depress, free, repeat) can increase bone mass has attracted attention recently. However, a definitive drug and dose regimen for this therapy has not been established yet. We treated 14 patients with senile or postmenopausal osteoporosis by our own methods, using repeated short cycles of drugs. Patients first received 2 μg/day of oral 1α-OH-D3 for 2weeks. During the following 2 weeks, they received 0.5 μg/day of oral 1α-OH-D3 plus 20 units of eel calcitonin or 40 MRC units of porcine calcitonin twice a week. Finally, 0.75 μg of 1α-OH-D3 and 3 g of calcium lactate were given orally daily for 8 weeks. This 12 week course was then repeated. The bone mineral content (CaCO3 mg/cm3), as assessed by QCT, increased singificantly from 3months onwards. The increase rates after 1 and 2 years were 14.2 and 18.2%, respectively. Serum osteocalcin levels increased from 6 months onwards, indicating acceleration of bone metabolism. These results suggest that, with this therapy, an early increase in bone mass and maintenance of that increase can be expected.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Farley, J.R. and Baylink D.J.: Pulification of a skeletal growth factor from human bone. Biochemistry 21:3502–3507, 1982
Frost, H.M.: Treatment of osteoporosis by manipulation of coherent bone cell populations. Clin. Orthop. 143:227–244, 1979
Hasling C. et al: Exogenous triiodothyronine activates bone remodeling. Bone 8(2):65–69, 1987
Inoue T.: Epidemiology of osteoporosis. Biomedical & Therapeutics 10:188–191, 1983
Kaneko N.: Influence of active vitamin D on bones, J. Jpn. Orthop. Assoc. 53:1823–1837, 1979
Kishimoto H. et al: Sequential therapy for osteoporosis;radial BMC monitoring. Orthopedic Surgery, 36(3):269–276, 1985
Pacifici R. et al: Coherence therapy dose not prevent axial bone loss in osteoporotic women:a preliminary comparative study, J. Clin. Endocrinol. Metab. 66(4):747–753, 1988
Sasaki S.: Biochemistry of organic bone matrix. The Bone 1(1):37–42, 1987
Sato N. & Suda A. et al: A study on senile osteoporosis in a mountain village. J. Jpn. Orthop. Assoc. 63(2), S491, 1989
Shin M.S. and Anderson, C.: Coherence therapy for postmenopausal osteoporosis, a histomorphometric study, The fifth international congress on bone morphometry, 1988, Nigata, Japan, p87
Suda, A. et al: Experimental studies on the mechanism of osteoclastic bone dissolution, Orthopedic Research Science 4, Physiology, Metabolism and Disease of Bone and Cartilage, 129–135, 1977(in Japan)
Suda A.: Effects of vitamin and hormone for bone. Orthopedic Research Science 10, Physiology, Metabolism and Disease of Bone and Cartilage, 351–354, 1983
Suda A, et al: Effects of calcitonin or combined treatment by calcitonin, 1α-OH-D3 and calcium for osteoporosis. Orthopedic Research Science 9, Physiology, Metabolism and Disease of Bone and Cartilage, 31∼34, 1982
Suda A. et al: ADSR therapy of osteoporosis. J. Jpn. Assoc., 62(9):s1275, 1988
Suda T.: Mechanism of calcification, “Hone no Hagaku”, Ishiyaku Publishers, 1987, p139
Takahashi H.: Combined or sequential treatment of osteoporosis. Biomedicine & Therapeutics, 10:253–259, 1983
Tanaka H. et al: 23(S)25(R)-1, 25(OH)D-26, 23 Lactone stimulates bone formation in vivo. Vitamin D Molecular, Cellular and Clinical Endocrinology, 1988, Walter de Gruyter & Co., Berlin, New York— Printed in Germany, p 610
Author information
Authors and Affiliations
Additional information
Running title: Bone mass changes in ADSR treatment
About this article
Cite this article
Suda, A. QCT study on changes in bone mass during sequential treatment (ADSR therapy) for osteoporosis. JBMM 7, 34–41 (1989). https://doi.org/10.1007/BF02911532
Issue Date:
DOI: https://doi.org/10.1007/BF02911532